AcouSort travels to Japan to re-ignite marketing efforts as the country opens up after the pandemic
AcouSort has been established on the Japanese market since 2019 when the company signed an exclusive distribution agreement with its Japanese partner Physio-Tech. The same year AcouSort also initiated a collaboration with a leading Japanese life science company. After almost three years of stringent restrictions, Japan has now opened up the country for overseas visitors. As one of the world’s largest healthcare markets, Japan is a prioritized market for AcouSort and a team of representatives will now travel east to re-ignite the marketing efforts.
The AcouSort team will visit the company’s distributor Physio-Tech to jointly exhibit AcouSort’s products at JSEV (Japanese Society for Extracellular Vesicles), an event which gathers Japan’s leading scientists in the field. Together with Physio-Tech, AcouSort will also conduct product and technology demonstrations at a number of international life science companies based in Japan. During the visit, the AcouSort team will train the colleagues at Physio-Tech on the latest application updates.
“The Japanese market is very important for AcouSort given its size and technological maturity. The pandemic struck shortly after we had made the first inroads in Japan, causing us to lose some of the momentum we had created. Now we are thrilled to again visit our Japanese partners to renew our joint efforts to establish a profitable presence on this significant healthcare market,” says AcouSort’s Commercial Director Agnes Michanek.
For further information on AcouSort, please contact:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Erik Penser Bank, 08-463 83 00, mail to: email@example.com Erik Penser Bank AB (publ), Apelbergsgatan 27, Box 7405, 103 91 Stockholm.